The effect of peripheral administration of growth hormone on AD-like cognitive deficiency in NBM-lesioned rats.
This study aimed to evaluate the peripheral administration of growth hormone (GH) on AD-like cognitive deficiency in NBM-lesioned rats induced by ibotenic acid (5 microg/microl, in each side). Forty-eight male Wistar rats (20-24 months old; weighing 330+/-30 g) randomly divided into six groups (n=8). The groups include control group, which were intact rats; n-L+GH group: non-lesioned rats with GH treatment (1mg/kg, 9.00 am, for 10 consecutive days); n-L+Veh group: non-lesioned rats with vehicle treatment; L group: NBM-lesioned rats; L+GH group: NBM-lesioned rats with GH treatment and L+Veh group: NBM-lesioned rats with same volume of vehicle treatment. Peripheral administration of GH in control had no effect on learning and memory, while in L+GH group produced a significant enhancement in spatial learning and memory comparing to L and L+Veh groups. The percent of time spent in goal quarter during probe trial has decreased significantly in L and L+Veh groups compared to n-L groups. While it has increased significantly in L+GH group compared to L and L+Veh groups. No significant difference in percent of time spent was seen between the control and n-L groups. The GH has known as a mediate that effect through IGF-1. As the IGF-1 itself is earlier shown to improve cognitive function it is likely that the observed effect of GH is mediated through release of IGF-1 from peripheral tissue into the circulation for further transport across the BBB. This mechanism may result in the improvement of learning and memory in rats with NBM lesion.
Doulah
A H
AH
Department of Biology, Sciences & Research Branch, Islamic Azad University (IAU), Poonak Squar, Ashrafi Isfehani High Way, Tehran, Iran.
Rohani
A Haeri
AH
Khaksari Haddad
M
M
Motamedi
F
F
Farbood
Y
Y
Badavi
M
M
Malek
M
M
Sarkaki
A
A
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D000818:Animals; D020532:Basal Nucleus of Meynert / Q000473:pathology*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D004195:Disease Models, Animal; D013006:Growth Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007858:Learning / Q000187:drug effects; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008568:Memory / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar
D013006:Growth Hormone